BWAY (BrainsWay) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BWAY BrainsWay Ltd BWAY
65 GF Score
Price $16.36
GF Value $7.23
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BrainsWay Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BWAY
65GF Score
BrainsWay Ltd BWAY
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BrainsWay (BWAY) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of $16.36 is trading 126.2% above its estimated GF Value™ of $7.23. GuruFocus considers BrainsWay to be Significantly Overvalued.

Key valuation signals for BWAY:

  • Dividends Received:
  • GF Value™: $7.23 vs. price of $16.36 (126.2% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the BWAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BrainsWay Business Description

Other Exchanges BWAY:Israel
Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
65GF Score

Get the complete analysis for BWAY

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.36
Price
$7.23
GF Value